Top Story
Rough Road Ahead for Innovation
With the continuing attacks on industry pricing and marketing practices, the last few months have been tough for pharmaceutical companies — and the political environment in Washington isn’t likely to improve in the coming year, writes Jill Wechsler
...Read more |
 |
Regulatory
CDER’s Long To-Do List for 2016
Center for Drug Evaluation (CDER) director Janet Woodcock’s priority list for 2016 highlights the need to further implement other legislative mandates such as drug compounding, track-and-trace, and sunscreen oversight, she explained at the FDA/CMS Summit earlier this month
...Read more |
 |
Value
The Payer Perspective
Payers, physicians, patients, and pharmaceutical companies each use a different lexicon when defining and discussing value. But can we use a broader understanding of stakeholders’ definitions to support new commercial engagement approaches? The answer is yes, writes Susan Abedi
...Read more |
In this paper, IMS Health describes the next generation of sales, marketing and technology - Orchestrated Customer Engagement (OCE). OCE seamlessly marshals the sequence, context, and purpose of messages to multiple influencing stakeholders.
 Learn More
|
Special Feature
The Healing Art in Medicine
Pharm Exec talks with David Dosa, a leading physician in geriatric medicine, whose famous work with a cat named Oscar in end-of-life diagnostics became the stuff of therapeutic legend
...Read more |
AmerisourceBergen
Patient-Centric Approach to Product Commercialization. In order for the patient to emerge center stage in a commercial approach, it's necessary for manufacturers to shift prioritization's to help the greatest number of patients gain access and remain on treatments. This requires aligning both R&D and marketing efforts with patient needs in order to drive positive outcomes— clinical as well as behavioral. The result is a successful product with far greater commercial value in a crowded and highly competitive market.
 Click here for more information.
|
 |
 //Novavax (Gaithersburg, MD) announced the appointment of Mark Twyman as Vice President, Marketing. Mr. Twyman will be focused on the commercial launch of the company’s RSV F Vaccine.//Assembly Biosciences (Indianapolis, IN) appointed Alan J. Lewis, Ph.D., to the company’s Board of Directors.//Achillion Pharmaceuticals (New Haven, CT) announced the appointment of Frank Verwiel, M.D., former President and Chief Executive Officer of Aptalis Pharma, to its Board of Directors.//CoLucid Pharmaceuticals (Cambridge, MA) appointed Raymond D. Skwierczynski, Ph.D., as Head, Pharmaceutical Operations.//
|
|
|
|
|
